Autoimmune Disease Diagnostics Market, 2012 to 2023
Market Outline: Autoimmune Disease Diagnostics Market
The immune system protects the body from infections and diseases. In autoimmune disorders low or overactivity of immune system may appear. There is no exact cause of autoimmune diseases are identified. In response to unknown trigger, immune system produces antibodies that instead of fighting infections, attacks body own tissues. Autoimmune diseases diagnosed with blood tests and review of disease history, symptoms and physical examination. Rheumatoid arthritis, type-1 diabetes, multiple sclerosis and lupus some of the major autoimmune diseases.
Market Dynamics: Autoimmune Disease Diagnostics Market
Global autoimmune disease diagnostics market is driven by government initiatives towards increasing awareness in public about autoimmune disorders. In addition, increase in R&D investments and rising prevalence of autoimmune disorders are expected to boost the global autoimmune disease diagnostics market. However, high cost of diagnosis, limited awareness in developing and underdeveloped countries are expected to hinder the market growth. In addition, chances of false results coupled with lack of skilled professionals are expected to hamper the global autoimmune disease diagnostics market over the forecast period.
Market Scope: Autoimmune Disease Diagnostics Market
Global Autoimmune Disease Diagnostics market is segmented based on type, disease and end-user
Based on type, global autoimmune disease diagnostics are segmented into
Systemic Autoimmune Disease
Local Autoimmune Disease
Based on disease, it is segmented into
Diabetes Type-1
Rheumatoid Arthritis
Multiple Sclerosis
Others
Based on end user,it is segmented into
Diagnostic Centers
Hospitals
Research Laboratories
Others
Market Summary: Autoimmune Disease Diagnostics Market
Global autoimmune disease diagnostics market is expected to grow at significant rate owing to growing rates of autoimmune diseases. According to National Multiple Sclerosis Society (MS), approximately, 2.3 Mn people are living with multiple sclerosis worldwide. The market is composed of multinational and local companies involved in offering autoimmune diagnostics. Major players are involving in R&D for development and introduction of new diagnostics into the market. Market players are collaborating in order to develop the new diagnostics for the autoimmune diseases and further increasing the market portfolio. For instance, in November 2014, Protagen AG entered into a long-term collaboration with Qiagen to develop an innovative companion diagnostic development platform for autoimmune disorders. Furthermore, government and non-profit organizations are taking initiatives to increase the awareness and involving in development of diagnostics for autoimmune diseases.
Regional Analysis: Autoimmune Disease Diagnostics Market
Geographically, global autoimmune disease diagnostics market is segmented into following regions, viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to be major market for autoimmune disease diagnostics owing to increase in prevalence of autoimmune disorders, presence of many market players, and government initiatives to promote the autoimmune disease awareness. Europe is expected to expand at significant growth rate for global autoimmune disease diagnostics due to growing awareness and rising prevalence of autoimmune diseases. Asia-Pacific is expected to grow at faster rates owing to expansion of MNC’s into the developing countries of the region such as India.
Competition Assessment: Autoimmune Disease Diagnostics Market
Some of the players in global autoimmune disease diagnostics market are Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux SA (France), Siemens AG (Siemens Healthineers) (Germany), Inova Diagnostics Inc. (Werfen Life Group, S.A.(Spain), Bio-Rad Laboratories (U.S.), MBL International Corporation (U.S.) and Quest Diagnostics Inc. (U.S.)
Market Developments: Autoimmune Disease Diagnostics Market
In November 2016, U.S. FDA has cleared Inova Diagnostic’s assay, “QUANTA LITE Calprotectin Extended Range” to help differentiate inflammatory bowel disease from irritating bowel disease.
In November 2014, Adaptive Biotechnologies launched, immunoSEQ, research use only kit for diagnosing autoimmune.
The immune system protects the body from infections and diseases. In autoimmune disorders low or overactivity of immune system may appear. There is no exact cause of autoimmune diseases are identified. In response to unknown trigger, immune system produces antibodies that instead of fighting infections, attacks body own tissues. Autoimmune diseases diagnosed with blood tests and review of disease history, symptoms and physical examination. Rheumatoid arthritis, type-1 diabetes, multiple sclerosis and lupus some of the major autoimmune diseases.
Market Dynamics: Autoimmune Disease Diagnostics Market
Global autoimmune disease diagnostics market is driven by government initiatives towards increasing awareness in public about autoimmune disorders. In addition, increase in R&D investments and rising prevalence of autoimmune disorders are expected to boost the global autoimmune disease diagnostics market. However, high cost of diagnosis, limited awareness in developing and underdeveloped countries are expected to hinder the market growth. In addition, chances of false results coupled with lack of skilled professionals are expected to hamper the global autoimmune disease diagnostics market over the forecast period.
Market Scope: Autoimmune Disease Diagnostics Market
Global Autoimmune Disease Diagnostics market is segmented based on type, disease and end-user
Based on type, global autoimmune disease diagnostics are segmented into
Systemic Autoimmune Disease
Local Autoimmune Disease
Based on disease, it is segmented into
Diabetes Type-1
Rheumatoid Arthritis
Multiple Sclerosis
Others
Based on end user,it is segmented into
Diagnostic Centers
Hospitals
Research Laboratories
Others
Market Summary: Autoimmune Disease Diagnostics Market
Global autoimmune disease diagnostics market is expected to grow at significant rate owing to growing rates of autoimmune diseases. According to National Multiple Sclerosis Society (MS), approximately, 2.3 Mn people are living with multiple sclerosis worldwide. The market is composed of multinational and local companies involved in offering autoimmune diagnostics. Major players are involving in R&D for development and introduction of new diagnostics into the market. Market players are collaborating in order to develop the new diagnostics for the autoimmune diseases and further increasing the market portfolio. For instance, in November 2014, Protagen AG entered into a long-term collaboration with Qiagen to develop an innovative companion diagnostic development platform for autoimmune disorders. Furthermore, government and non-profit organizations are taking initiatives to increase the awareness and involving in development of diagnostics for autoimmune diseases.
Regional Analysis: Autoimmune Disease Diagnostics Market
Geographically, global autoimmune disease diagnostics market is segmented into following regions, viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to be major market for autoimmune disease diagnostics owing to increase in prevalence of autoimmune disorders, presence of many market players, and government initiatives to promote the autoimmune disease awareness. Europe is expected to expand at significant growth rate for global autoimmune disease diagnostics due to growing awareness and rising prevalence of autoimmune diseases. Asia-Pacific is expected to grow at faster rates owing to expansion of MNC’s into the developing countries of the region such as India.
Competition Assessment: Autoimmune Disease Diagnostics Market
Some of the players in global autoimmune disease diagnostics market are Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux SA (France), Siemens AG (Siemens Healthineers) (Germany), Inova Diagnostics Inc. (Werfen Life Group, S.A.(Spain), Bio-Rad Laboratories (U.S.), MBL International Corporation (U.S.) and Quest Diagnostics Inc. (U.S.)
Market Developments: Autoimmune Disease Diagnostics Market
In November 2016, U.S. FDA has cleared Inova Diagnostic’s assay, “QUANTA LITE Calprotectin Extended Range” to help differentiate inflammatory bowel disease from irritating bowel disease.
In November 2014, Adaptive Biotechnologies launched, immunoSEQ, research use only kit for diagnosing autoimmune.
1. EXECUTIVE SUMMARY
2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET INTRODUCTION
2.1. Global Autoimmune Disease Diagnostics Market – Taxonomy
2.2. Global Autoimmune Disease Diagnostics Market –Definitions
2.2.1. Type
2.2.2. Disease Type
2.2.3. End User
2.2.4. Region
3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Autoimmune Disease Diagnostics Market Dynamics – Factors Impact Analysis
3.6. Global Autoimmune Disease Diagnostics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Autoimmune Disease Diagnostics Market – Product Innovations
4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Type Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Systemic Autoimmune Disease
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Local Autoimmune Disease
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Diabetes Type-1
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Rheumatoid Arthritis
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Multiple Sclerosis
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.4.3. Market Opportunity Analysis
7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Diagnostic Centers
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Hospitals
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Research Laboratories
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis
8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease Type, End User, and Region, 2017 – 2023
9. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.2. Systemic Autoimmune Disease
9.1.3. Local Autoimmune Disease
9.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.5. Diabetes Type-1
9.1.6. Rheumatoid Arthritis
9.1.7. Multiple Sclerosis
9.1.8. Others
9.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.10. Diagnostic Centers
9.1.11. Hospitals
9.1.12. Research Laboratories
9.1.13. Others
9.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.14.1. U.S.
9.1.14.2. Canada
9.1.15. North America Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease, End User and Country, 2017 – 2023
9.1.16. North America Autoimmune Disease Diagnostics Market Dynamics – Trends
10. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Systemic Autoimmune Disease
10.1.3. Local Autoimmune Disease
10.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.5. Diabetes Type-1
10.1.6. Rheumatoid Arthritis
10.1.7. Multiple Sclerosis
10.1.8. Others
10.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.10. Diagnostic Centers
10.1.11. Hospitals
10.1.12. Research Laboratories
10.1.13. Others
10.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.14.1. Germany
10.1.14.2. UK
10.1.14.3. France
10.1.14.4. Spain
10.1.14.5. Italy
10.1.14.6. Russia
10.1.14.7. Poland
10.1.14.8. Rest of Europe
10.1.15. Europe Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease, End User, and Country, 2017 – 2023
10.1.16. Europe Autoimmune Disease Diagnostics Market Dynamics – Trends
11. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Systemic Autoimmune Disease
11.1.3. Local Autoimmune Disease
11.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5. Diabetes Type-1
11.1.6. Rheumatoid Arthritis
11.1.7. Multiple Sclerosis
11.1.8. Others
11.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.10. Diagnostic Centers
11.1.11. Hospitals
11.1.12. Research Laboratories
11.1.13. Others
11.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.14.1. Japan
11.1.14.2. China
11.1.14.3. India
11.1.14.4. ASEAN
11.1.14.5. Australia & New Zealand
11.1.14.6. Rest of Asia-Pacific
11.1.15. Asia-Pacific Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, End User, and Country, 2017 – 2023
11.1.16. Asia-Pacific Autoimmune Disease Diagnostics Market Dynamics – Trends
12. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Systemic Autoimmune Disease
12.1.3. Local Autoimmune Disease
12.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.5. Diabetes Type-1
12.1.6. Rheumatoid Arthritis
12.1.7. Multiple Sclerosis
12.1.8. Others
12.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.10. Diagnostic Centers
12.1.11. Hospitals
12.1.12. Research Laboratories
12.1.13. Others
12.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.14.1. Brazil
12.1.14.2. Mexico
12.1.14.3. Argentina
12.1.14.4. Venezuela
12.1.14.5. Rest of Latin America
12.1.15. Latin America Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease, End User, and Country, 2017 – 2023
12.1.16. Latin America Autoimmune Disease Diagnostics Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2. Systemic Autoimmune Disease
13.1.3. Local Autoimmune Disease
13.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5. Diabetes Type-1
13.1.6. Rheumatoid Arthritis
13.1.7. Multiple Sclerosis
13.1.8. Others
13.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.10. Diagnostic Centers
13.1.11. Hospitals
13.1.12. Research Laboratories
13.1.13. Others
13.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.14.1. Gulf Cooperation Council (GCC) Countries
13.1.14.2. Israel
13.1.14.3. South Africa
13.1.14.4. Rest of MEA
13.1.15. MEA Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease, End User, and Country, 2017 – 2023
13.1.16. MEA Autoimmune Disease Diagnostics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Beckman Coulter, Inc. (U.S.)
14.2.2. Abbott Laboratories (U.S.)
14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)
14.2.4. bioMerieux SA (France)
14.2.5. Siemens AG (Siemens Healthineers) (Germany)
14.2.6. Inova Diagnostics Inc. (Werfen Life Group, S.A.(Spain)
14.2.7. Bio-Rad Laboratories (U.S.)
14.2.8. MBL International Corporation (U.S.)
14.2.9. Quest Diagnostics Inc. (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET INTRODUCTION
2.1. Global Autoimmune Disease Diagnostics Market – Taxonomy
2.2. Global Autoimmune Disease Diagnostics Market –Definitions
2.2.1. Type
2.2.2. Disease Type
2.2.3. End User
2.2.4. Region
3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Autoimmune Disease Diagnostics Market Dynamics – Factors Impact Analysis
3.6. Global Autoimmune Disease Diagnostics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Autoimmune Disease Diagnostics Market – Product Innovations
4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, BY TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Type Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Systemic Autoimmune Disease
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Local Autoimmune Disease
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Diabetes Type-1
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Rheumatoid Arthritis
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Multiple Sclerosis
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.4.3. Market Opportunity Analysis
7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Diagnostic Centers
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Hospitals
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Research Laboratories
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis
8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease Type, End User, and Region, 2017 – 2023
9. NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.2. Systemic Autoimmune Disease
9.1.3. Local Autoimmune Disease
9.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.5. Diabetes Type-1
9.1.6. Rheumatoid Arthritis
9.1.7. Multiple Sclerosis
9.1.8. Others
9.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.10. Diagnostic Centers
9.1.11. Hospitals
9.1.12. Research Laboratories
9.1.13. Others
9.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.14.1. U.S.
9.1.14.2. Canada
9.1.15. North America Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease, End User and Country, 2017 – 2023
9.1.16. North America Autoimmune Disease Diagnostics Market Dynamics – Trends
10. EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Systemic Autoimmune Disease
10.1.3. Local Autoimmune Disease
10.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.5. Diabetes Type-1
10.1.6. Rheumatoid Arthritis
10.1.7. Multiple Sclerosis
10.1.8. Others
10.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.10. Diagnostic Centers
10.1.11. Hospitals
10.1.12. Research Laboratories
10.1.13. Others
10.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.14.1. Germany
10.1.14.2. UK
10.1.14.3. France
10.1.14.4. Spain
10.1.14.5. Italy
10.1.14.6. Russia
10.1.14.7. Poland
10.1.14.8. Rest of Europe
10.1.15. Europe Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease, End User, and Country, 2017 – 2023
10.1.16. Europe Autoimmune Disease Diagnostics Market Dynamics – Trends
11. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Systemic Autoimmune Disease
11.1.3. Local Autoimmune Disease
11.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5. Diabetes Type-1
11.1.6. Rheumatoid Arthritis
11.1.7. Multiple Sclerosis
11.1.8. Others
11.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.10. Diagnostic Centers
11.1.11. Hospitals
11.1.12. Research Laboratories
11.1.13. Others
11.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.14.1. Japan
11.1.14.2. China
11.1.14.3. India
11.1.14.4. ASEAN
11.1.14.5. Australia & New Zealand
11.1.14.6. Rest of Asia-Pacific
11.1.15. Asia-Pacific Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, End User, and Country, 2017 – 2023
11.1.16. Asia-Pacific Autoimmune Disease Diagnostics Market Dynamics – Trends
12. LATIN AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Systemic Autoimmune Disease
12.1.3. Local Autoimmune Disease
12.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.5. Diabetes Type-1
12.1.6. Rheumatoid Arthritis
12.1.7. Multiple Sclerosis
12.1.8. Others
12.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.10. Diagnostic Centers
12.1.11. Hospitals
12.1.12. Research Laboratories
12.1.13. Others
12.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.14.1. Brazil
12.1.14.2. Mexico
12.1.14.3. Argentina
12.1.14.4. Venezuela
12.1.14.5. Rest of Latin America
12.1.15. Latin America Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease, End User, and Country, 2017 – 2023
12.1.16. Latin America Autoimmune Disease Diagnostics Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2. Systemic Autoimmune Disease
13.1.3. Local Autoimmune Disease
13.1.4. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5. Diabetes Type-1
13.1.6. Rheumatoid Arthritis
13.1.7. Multiple Sclerosis
13.1.8. Others
13.1.9. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.10. Diagnostic Centers
13.1.11. Hospitals
13.1.12. Research Laboratories
13.1.13. Others
13.1.14. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.14.1. Gulf Cooperation Council (GCC) Countries
13.1.14.2. Israel
13.1.14.3. South Africa
13.1.14.4. Rest of MEA
13.1.15. MEA Autoimmune Disease Diagnostics Market - Opportunity Analysis Index, By Type, Disease, End User, and Country, 2017 – 2023
13.1.16. MEA Autoimmune Disease Diagnostics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Beckman Coulter, Inc. (U.S.)
14.2.2. Abbott Laboratories (U.S.)
14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)
14.2.4. bioMerieux SA (France)
14.2.5. Siemens AG (Siemens Healthineers) (Germany)
14.2.6. Inova Diagnostics Inc. (Werfen Life Group, S.A.(Spain)
14.2.7. Bio-Rad Laboratories (U.S.)
14.2.8. MBL International Corporation (U.S.)
14.2.9. Quest Diagnostics Inc. (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
